Why the study?
Does manipulating brain angiotensin with ARBs or ACE inhibitors prevent neuroinflammation and dopaminergic degeneration in Parkinson's disease?
Population
Animal models of Parkinson's disease and general discussion of Parkinson's disease
Design
Review
Authors
Loading...
May warrant trials of ARBs/ACEIs for Parkinson's neuroprotection; hypothesis-generating from animal data alone.
Does manipulating brain angiotensin with ARBs or ACE inhibitors prevent neuroinflammation and dopaminergic degeneration in Parkinson's disease?
Manipulating brain angiotensin with ARBs or ACE inhibitors may constitute an effective neuroprotective strategy for Parkinson's disease by reducing neuroinflammation and oxidative stress.
Labandeira‐García et al. (2013) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: